Business Operations Centered on In-House Company Management
First written in FY2016. 24 of 31 entries say "Restated". Latest entry: 2026-08-07.
Terumo moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2019: 1 of 9 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- 2026-08-07RestatedEarnings
「Accordingly, the Company has four reportable segments: the Cardiovascular Company, the Medical Care Solutions Company, the Blood and Cell Technologies Company, and the Organ Technologies Business, which are organized based on the in-house company structure or product-group-based segments.」
The Company reaffirmed its operation of four reportable segments based on the in-house company structure. - FY2026ReframedAnnual report
「Following the acquisition of all shares of OrganOx, Ltd. on 29 October 2025 and its conversion into a wholly owned subsidiary, the company added “Organ Technologies Business” as a new reporting segment from the current fiscal year.」
The company expanded its reporting segments from 3 to 4 businesses by adding Organ Technologies Business following the conversion of OrganOx into a wholly owned subsidiary, while retaining operations based on the former 3-company structure. - 2026-05-15ReframedEarnings
「Accordingly, the Company has four reportable segments: the Cardiovascular Company, the Medical Care Solutions Company, the Blood and Cell Technologies Company, and the Organ Technologies Business, which are organized based on the in-house company structure or product-group-based segments.」
The Company reorganized its reporting structure into four reportable segments by adding the Organ Technologies Business, following the acquisition of OrganOx, to the reporting units based on the former three companies. - FY2025ReframedAnnual report
「Effective 1 April 2025, the company changed the names of certain businesses within Cardiovascular Company and changed the disclosed segment for Blood and Cell Technologies Company.」
Operations based on the 3-company structure continue, but from April 2025, certain business names within Cardiovascular Company and the disclosed segment for Blood and Cell Technologies Company were reorganized to align with the unification of business brands and organizational changes. - FY2025-H1RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to explicitly state its business operations under an in-house company structure organized by product group, with the 3 companies serving as reporting segments and management units. - FY2024ReframedAnnual report
「The company also continued discussions aimed at further improving the efficiency of its 3-axis management framework—business, functions, and regions—and strengthening governance.」
In addition to the former product-group-based company management structure, the company has organized its management framework around 3 axes—business, functions, and regions—to improve management efficiency and strengthen governance. - FY2024-Q3RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to adopt business operations based on an in-house company structure organized by product group, with the 3 companies serving as reporting and management units. - FY2024-Q2RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to adopt business operations based on an in-house company structure organized by product group, with the 3 companies serving as reporting and management units. - FY2024-Q1RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to operate with the 3 companies serving as its reporting and management units under an in-house company structure organized by product group. - FY2023-Q3RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to describe operations under an in-house company structure organized by product group, with the 3 companies serving as reporting segments and management units. - FY2023-Q2RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly. Accordingly, the company has 3 reporting segments consisting of product-group-based in-house companies: Cardiovascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.」
The company continues to operate with the 3 companies serving as its reporting and management units under an in-house company structure organized by product group. - FY2023-Q1RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly.」
The company continues to formulate strategies and conduct business operations in Japan and overseas across 3 reporting segments—Cardiovascular, Medical Care Solutions, and Blood and Cell Technologies—under an in-house company structure organized by product group. - FY2022ReframedAnnual report
「In addition, from the current consolidated fiscal year, the former segment name “Hospital Company” has been changed to “Medical Care Solutions Company.”」
Operations by the 3 companies continued, but Hospital Company was renamed Medical Care Solutions Company and reorganized as a new business area encompassing solution businesses. - FY2022-Q3RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to describe operations under an in-house company structure organized by product group, with each company headquarters formulating comprehensive strategies for Japan and overseas markets. - FY2022-Q2RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to describe operations under an in-house company structure organized by product group, with each company headquarters formulating comprehensive strategies for Japan and overseas markets. - FY2022-Q1RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly.」
The company continues to describe operations under an in-house company structure organized by product group, with each company headquarters formulating comprehensive strategies for Japan and overseas markets. - FY2021RestatedAnnual report
「The Group has adopted an in-house company structure organized by product group. Each in-house company headquarters formulates comprehensive strategies for the products it handles in Japan and overseas and conducts business activities accordingly.」
The company continues to base its business operations on an in-house company structure organized by product group and comprehensive strategy formulation by each company for Japan and overseas markets. - FY2021-Q3RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to describe operations under an in-house company structure organized by product group, with each company headquarters formulating comprehensive strategies for Japan and overseas markets. - FY2021-Q1RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to describe operations under an in-house company structure organized by product group, with each company formulating comprehensive strategies for Japan and overseas markets. - FY2020ReframedAnnual report
「In addition, from the current consolidated fiscal year, the former segment name “Blood Systems Company” has been changed to “Blood and Cell Technologies Company.”」
Operations continued under the 3-company structure, but Blood Systems Company was renamed Blood and Cell Technologies Company and reorganized as a business area encompassing cell technologies. - FY2020-Q3RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to operate under an in-house company structure organized by product group, with each company formulating comprehensive strategies for Japan and overseas markets. - FY2020-Q2RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to describe its operations under an in-house company structure, with management resources allocated and performance evaluated across 3 reporting segments—Cardiovascular, Hospital, and Blood Systems. - FY2019RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to formulate strategies and conduct business operations in Japan and overseas across 3 reporting segments—Cardiovascular, Hospital, and Blood Systems—under its in-house company structure. - FY2019-Q3RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to operate under its in-house company structure, with each company formulating comprehensive strategies for Japan and overseas markets. - FY2019-Q2RestatedAnnual report
「The Group has adopted an in-house company system organized by product group. Each in-house company headquarters formulates comprehensive domestic and overseas strategies for the products it handles and conducts business activities accordingly.」
The company continues to allocate management resources and evaluate performance across 3 reporting segments—Cardiovascular, Hospital, and Blood Systems—under its in-house company structure. - FY2018-Q3RestatedAnnual report
「The status of revenue by business segment is as follows.」
It continues to operate with the Cardiovascular, Hospital, and Blood Systems companies as the units for explaining and managing business conditions. - FY2018-Q2RestatedAnnual report
「The status of revenue by business segment is as follows.」
It continues to operate with the Cardiovascular, Hospital, and Blood Systems companies as the units for explaining and managing business conditions. - FY2017-Q3RestatedAnnual report
「The main points for each company are as follows.」
It continues to use an operating model that explains business conditions by company: Cardiovascular, Hospital, and Blood Systems. - FY2017-Q2RestatedAnnual report
「Against this backdrop, the Group is currently pursuing management with company-based management as its core, under the goal of “becoming a globally prominent company,” and aims to achieve sustainable, profitable, high-quality growth.」
It continues to explicitly state a business operating policy centered on company management. - FY2017-Q1RestatedAnnual report
「The Group is currently pursuing management aimed at achieving sustainable, profitable, high-quality growth centered on company management, under the goal of becoming a company with a strong presence worldwide.」
It continues to explicitly state an operating policy centered on company management. - FY2016First statedAnnual report
「The Group is currently pursuing management aimed at achieving sustainable, profitable, high-quality growth centered on company management, under the goal of becoming a company with a strong presence worldwide.」
The Cardiovascular, Hospital, and Blood Systems companies are operated as the units for allocating management resources and evaluating performance.